BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/12/2026 6:40:17 AM | Browse: 10 | Download: 26
 |
Received |
|
2026-03-12 01:45 |
|
Peer-Review Started |
|
2026-03-12 01:49 |
|
First Decision by Editorial Office Director |
|
2026-03-20 10:42 |
|
Return for Revision |
|
2026-03-20 10:42 |
|
Revised |
|
2026-04-01 09:02 |
|
Publication Fee Transferred |
|
2026-04-22 09:36 |
|
Second Decision by Editor |
|
2026-04-22 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-22 06:13 |
|
Articles in Press |
|
2026-04-22 06:13 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-07 01:45 |
|
Publish the Manuscript Online |
|
2026-05-12 06:40 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Dermatology |
| Manuscript Type |
Case Report |
| Article Title |
Kaposi sarcoma following dupilumab treatment for bullous pemphigoid: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sheng-Nan Wang, Jin-Meng Wang, Mian Xu and Jing-Jing Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jing-Jing Wu, MD, Department of Dermatology, Wenzhou Central Hospital, No.252 Baili East Road, Lucheng District, Wenzhou 325000, Zhejiang Province, China. 359680756@qq.com |
| Key Words |
Bullous pemphigoid; Dupilumab; Kaposi’s sarcoma; Interleukin-6/TYK2/STAT3; Kaposi sarcoma-associated herpesvirus; Herpesvirus 8; Immune evasion; Case report |
| Core Tip |
Dupilumab was used to treat bullous pemphigoid (BP) complicated with Kaposi sarcoma (KS). The causes were analyzed, and the immune drift induction hypothesis was proposed. STAT3 plays a key role in KS pathogenesis, as it supports human herpesvirus-8 latency and viral replication. It can be activated by virally encoded interleukin-6 via gp130 receptor signaling to promote the survival and proliferation of infected cells. Dupilumab-induced immune deviation (toward Th1/Th17/Th22 pathways) and STAT3 signaling activation may contribute to KS occurrence in susceptible BP patients. Further investigation is needed. |
| Publish Date |
2026-05-12 06:40 |
| Citation |
Wang SN, Wang JM, Xu M, Wu JJ. Kaposi sarcoma following dupilumab treatment for bullous pemphigoid: A case report and review of literature. World J Clin Cases 2026; 14(15): 120825 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i15/120825.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i15.120825 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
